Menu Search
Equities

Indoco Remedies Ltd

INDOCO:NSI

Indoco Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)320.05
  • Today's Change21.05 / 7.04%
  • Shares traded512.90k
  • 1 Year change-8.56%
  • Beta0.6713
Data delayed at least 15 minutes, as of Nov 22 2024 10:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Indoco Remedies Ltd have a median target of 320.00, with a high estimate of 341.00 and a low estimate of 295.00. The median estimate represents a -1.55% decrease from the last price of 325.05.
High4.9%341.00
Med-1.6%320.00
Low-9.2%295.00

Dividends

In 2024, Indoco Remedies Ltd reported a dividend of 1.50 INR, which represents a 33.33% decrease from last year. The 2 analysts covering the company expect dividends of 1.85 INR for the upcoming fiscal year, an increase of 23.33%.
Div growth (TTM)-33.33%
More ▼

Earnings history & estimates in INR

On May 16, 2024, earnings of 0.31 per share.
The next earnings announcement is expected on May 14, 2025.
Average growth rate-20.48%
Indoco Remedies Ltd reported annual 2024 earnings of 9.28 per share on May 16, 2024.
Average growth rate+75.95%
More ▼

Revenue history & estimates in INR

Indoco Remedies Limited had 2nd quarter 2025 revenues of 4.33bn. This missed the 4.61bn consensus estimate of the 2 analysts following the company. This was 1.44% above the prior year's 2nd quarter results.
Average growth rate-2.63%
Indoco Remedies Limited had revenues for the full year 2024 of 18.17bn. This was 8.91% above the prior year's results.
Average growth rate+14.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.